Staar Surgical Co
STAA Nasdaq· Ophthalmic Goods
Last close · Oct 26, 2026
$23.23
KIRA · Stoqly’s AI analyst, in plain words
- Staar Surgical Co had $239M of revenue in fiscal 2025, down 23.7% on the year before. Over five years, revenue changed +7.9% a year on average.
- Its operating margin was −38.3%, down 34.3 pts: of every 100 in sales, about −38 is left after running the business.
- Staar Surgical Co lost $80.4M in fiscal 2025.
- Free cash flow was −$40.1M in fiscal 2025, −16.7% of revenue.
- Staar Surgical Co returned $6.5M to shareholders in fiscal 2025. The diluted share count rose 0.9%.
Market cap
$1.2B
P/E
—
Revenue
$239M
Net income
−$80.4M
Free cash flow
−$40.1M
Operating margin
−38.3%
Staar Surgical Co in 30 seconds · fiscal 2025
Are sales growing?
−23.7%
No. Sales fell 23.7% last year.
Does it make a profit?
−33.6%
No. It lost money last year.
Does profit turn into cash?
−16.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
What Staar Surgical Co does
No business description yet.
- Fiscal year ends
- January 2, 2026
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- STAAR SURGICAL CO
- CIK
- 0000718937
Staar Surgical Co · STAA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $230M | $239M | $322M | $314M | $239M |
| Revenue growth | 41.0% | 3.9% | 34.7% | −2.6% | −23.7% |
| Gross margin | 77.5% | 93.3% | 78.4% | 76.3% | 76.2% |
| Operating margin | 14.5% | 18.3% | 8.7% | −4.0% | −38.3% |
| Net income | $27.5M | $39.7M | $21.3M | −$20.2M | −$80.4M |
| Net margin | 11.9% | 16.6% | 6.6% | −6.4% | −33.6% |
| Diluted EPS | $0.56 | $0.80 | $0.43 | −$0.41 | −$1.62 |
| Cash | |||||
| Cash from operations | $44.0M | $35.7M | $14.6M | $15.7M | −$34.2M |
| Capital expenditure | $13.6M | $18.1M | $18.2M | $23.4M | $5.8M |
| Free cash flow | $30.3M | $17.6M | −$3.6M | −$7.7M | −$40.1M |
| FCF margin | 13.2% | 7.4% | −1.1% | −2.4% | −16.7% |
| Share buybacks | — | — | — | — | $6.5M |
| Share count change | 3.1% | −0.2% | 0.1% | −0.6% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $200M | $212M | $221M | $230M | $188M |
| Shareholders' equity | $262M | $336M | $386M | $397M | $344M |
| Current ratio | 5.6x | 6.0x | 5.6x | 5.2x | 4.5x |
| Returns and quality | |||||
| Return on equity | 12.0% | 13.3% | 5.9% | −5.2% | −21.7% |
| Return on tangible equity | 10.6% | 11.9% | 5.6% | −5.1% | −23.5% |
| Piotroski F-score | 7 | 6 | 3 | 3 | 1 |
| Altman Z'' | 7.0 | 8.5 | 8.0 | 7.0 | 4.5 |
Insiders bought, 12 months
$62.8M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Staar Surgical Co · STAA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $23.23 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0000718937). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.